SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response

SBIR 第一阶段：高通量微流控平台，可加速应对 COVID-19 的生物制造转型

• 批准号: 2032448
• 负责人: Konstantinos Tsioris
• 金额: $ 25.6万
• 依托单位: ONECYTE BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2032448&HistoricalAwards=false
• 关键词: SBIR; Phase; throughput; microfluidic; platform

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to address a key challenge in the response to COVID-19, namely manufacturing sufficient quantities of novel therapeutics and vaccines. This project can shorten the development times of drugs by as much as 6 months, accelerating translation of new therapeutics. This technology will also enable more testing, thereby increasing the performance and potentially reducing the side effects of these drugs.This SBIR Phase I project advances the manufacturing of biologics, which starts with a high performing clonal cell line derived (by definition) from a single cell. Developing such a cell line today takes up to 6 months due to iterative screening and testing to assure quality and performance. The proposed project aims to enable selection of a high performing cell clone in one day compared to many months by using a proprietary single cell proteomics platform, at an unprecedented throughput rather than lengthy, iterative selection, clonal expansion and analytics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛的影响/商业潜力旨在应对对Covid-19的反应中的关键挑战，即制造足够数量的新型治疗剂和疫苗。该项目可以将药物的开发时间缩短多达6个月，从而加速了新治疗剂的翻译。这项技术还将实现更多的测试，从而提高性能并潜在地减少这些药物的副作用。该SBIR I期项目推进了生物制剂的制造，该项目始于从单个细胞中得出的高性能克隆细胞系（按定义）。由于迭代筛查和测试，今天最多需要6个月的时间来确保质量和性能。拟议的项目旨在通过使用专有的单细胞蛋白质组学平台在一天中选择高性能的细胞克隆，以前所未有的吞吐量，而不是冗长的，迭代的选择，克隆扩张和分析。这一奖项反映了NSF的法定任务，并通过评估委员会进行了评估，该奖项已被视为众所周知的范围，并反映了构成群体的范围。